drugset / Trial / NCT00129558
A Study to Evaluate PT-523 in Patients With Refractory Leukemia
Non-randomizedOpen-labelTreatment
Summary
This Phase I/II, multi-centered, non-randomized, trial is designed to determine a safe dose of PT-523 for subjects, and to make preliminary evaluations on the activity of PT-523 as therapy in subjects with refractory leukemia.
Timeline
- Start
- 2005-07
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PT-523 | Unknown | — | — |